Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Genetics/Genomes/Proteomics/Metabolomics

Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men

  1. Jagadish Vangipurapu1,
  2. Alena Stancáková1,
  3. Ulf Smith2,
  4. Johanna Kuusisto1,3 and
  5. Markku Laakso1,3⇑
  1. 1Internal Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
  2. 2Lundberg Laboratory for Diabetes Research, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  3. 3Department of Medicine, Kuopio University Hospital, Kuopio, Finland
  1. Corresponding author: Markku Laakso, markku.laakso{at}uef.fi
Diabetes 2019 Jun; 68(6): 1353-1358. https://doi.org/10.2337/db18-1076
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

Several amino acids (AAs) have been shown to be associated with insulin resistance and increased risk of type 2 diabetes, but no previous studies have investigated the association of AAs with insulin secretion in a longitudinal setting. Our study included 5,181 participants of the cross-sectional METabolic Syndrome In Men (METSIM) study having metabolomics data on 20 AAs. A total of 4,851 had a 7.4-year follow-up visit. Nine AAs (phenylalanine, tryptophan, tyrosine, alanine, isoleucine, leucine, valine, aspartate, and glutamate) were significantly (P < 5.8 × 10−5) associated with decreases in insulin secretion (disposition index) and the elevation of fasting or 2-h glucose levels. Five of these AAs (tyrosine, alanine, isoleucine, aspartate, and glutamate) were also found to be significantly associated with an increased risk of incident type 2 diabetes after adjustment for confounding factors. Our study is the first population-based large cohort to report that AAs are associated not only with insulin resistance but also with decreased insulin secretion.

Introduction

Type 2 diabetes is often preceded by a long period of prediabetes, characterized by insulin resistance and impaired insulin secretion. Conversion to diabetes happens when insulin secretion from the pancreas is no longer able to compensate for insulin resistance in peripheral insulin-sensitive tissues (1).

Several metabolites, including especially branched-chain amino acids (BCAAs) and aromatic amino acids, have been reported to be associated with the risk of type 2 diabetes in previous studies (2–5). However, most of these studies have been cross-sectional, and none of these studies has investigated the association of amino acids (AAs) with changes in insulin secretion in a longitudinal setting.

We investigated the associations of twenty AAs with insulin secretion, insulin resistance, and glycemia in a large Finnish prospective population-based METabolic Syndrome In Men (METSIM) cohort.

Research Design and Methods

Study Population, Methods, and Calculations

The METSIM study comprises 10,197 Finnish men, aged from 45 to 73 years, randomly selected from the population register of Kuopio town, Eastern Finland. The study design and laboratory methods have previously been described (6,7). Glucose tolerance was evaluated with a 2-h glucose tolerance test (OGTT) (75 g glucose) including three time points (glucose and insulin levels measured at 0, 30, and 120 min) according to the American Diabetes Association criteria (8). Of 5,181 men without diabetes at entry included in the present analysis, 4,851 participated in the follow-up study (mean follow-up time 7.4 ± 2.9 years). This subset of 5,181 men had clinical and laboratory characteristics (Supplementary Table 1) similar to those of the entire METSIM population without diabetes, and therefore this subsample can be considered to present the entire METSIM cohort (7). A total of 522 participants developed incident type 2 diabetes. The study was approved by the Ethics Committee of the University of Kuopio and Kuopio University Hospital. All study participants gave written informed consent.

Glucose and insulin areas under the curve (AUCs) in an OGTT were calculated by the trapezoidal method. The Matsuda insulin sensitivity index (Matsuda ISI) was calculated as previously published (9). Insulin secretion index (InsAUC0–30/GluAUC0–30) was calculated based on an OGTT as follows: (insulin at 0 min + insulin at 30 min)/ (glucose at 0 min + glucose at 30 min). The selection of Matsuda ISI (among 6 insulin sensitivity indices compared with the M value from euglycemic clamp) and InsAUC0–30/GluAUC0–30 (among 11 insulin secretion indices compared with insulin secretion during a frequently sampled intravenous glucose tolerance test) was based on our previous validation study (7). Disposition index (DI), a measure of insulin secretion adjusted for prevailing insulin sensitivity, was calculated as Matsuda ISI × (InsAUC0–30/GluAUC0–30) (7).

Metabolomics Analysis

Metabolites were measured as part of Metabolon's untargeted Discovery HD4 platform using ultra-high-performance liquid chromatography–tandem mass spectroscopy. All methods used a Waters ACQUITY UPLC and a Thermo Scientific Q Exactive high-resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. Raw data were extracted and quality control processed using Metabolon’s hardware and software. Peaks were quantified using AUC. For studies spanning multiple days, a data normalization step was performed to correct variation resulting from instrument interday tuning differences. Compounds were identified by comparison with library entries of purified standards or recurrent unknown entities. The metabolite levels were rescaled to have a median equal to 1.

The metabolomics analyses were performed in three batches. Batch 1 included 999 samples with 717 metabolites identified, batch 2 included 1,231 samples with 778 metabolites identified, and batch 3 included 3,000 samples with 843 metabolites identified. Twenty AAs from a total of 857 metabolites were included in current statistical analysis. The percentage of missing values for AAs was from 0 to 0.2%.

Statistical Analysis

We conducted statistical analyses using IBM SPSS Statistics, version 25. We log-transformed all continuous traits with the exception of age and follow-up time to correct for their skewed distribution. Intercorrelations between the AAs were calculated by Pearson correlations (Supplementary Fig. 1). We examined the association of AAs with Matsuda ISI, DI, and glucose levels with linear regression and presented the results as standardized regression coefficients (β and SE). We applied Cox regression to associate the levels of AAs with incident type 2 diabetes. P < 5.8 × 10−5 (corrected for 857 metabolites) was considered statistically significant and P < 0.05 nominally significant.

Results

Association of AAs With Insulin Sensitivity and Insulin Secretion

In our cross-sectional study all AAs, except for arginine, histidine, and threonine, were significantly (P < 5.8 × 10−5) associated with insulin sensitivity (Matsuda ISI) (Table 1). Glycine, serine, glutamine, and asparagine were associated with improved insulin sensitivity, whereas all other AAs were associated with decreased insulin sensitivity. Glutamate, tyrosine, isoleucine, and alanine had the largest effect on the reduction of insulin sensitivity. In a prospective study, the effect sizes of AAs on Matsuda ISI were substantially smaller than those in the baseline study. Only 6 of 20 AAs showed significant changes in Matsuda ISI during the follow-up. Glutamate, tyrosine, leucine, aspartate, and phenylalanine were associated with a decrease in Matsuda ISI, and glycine was associated with an increase in Matsuda ISI.

View this table:
  • View inline
  • View popup
Table 1

Associations of AAs with Matsuda ISI in the cross-sectional and 7.4-year prospective studies of the METSIM cohort

In a cross-sectional study, 14 AAs were significantly associated with a decrease in insulin secretion (DI); the most significant reductions in the DI were observed for glutamate, tyrosine, alanine, and isoleucine (Table 2). Glycine, glutamine, serine, and asparagine were associated with a significant increase in the DI. Nine of the 14 AAs that were significantly associated with the DI in the cross-sectional study remained significant also in the prospective study. The largest effects on the DI were observed for leucine, isoleucine, tyrosine, and glutamate.

View this table:
  • View inline
  • View popup
Table 2

Associations of AAs with the DI in the cross-sectional and 7.4-year prospective studies of the METSIM cohort

In the cross-sectional study, the effect sizes (β) of the AAs were significantly larger for insulin resistance (except for glycine and serine, which increased insulin sensitivity) than for reduction in insulin secretion (Supplementary Table 1 and Supplementary Fig. 2). By contrast, in the prospective study effect sizes for the reduction of insulin secretion were numerically larger compared with effect sizes for insulin resistance and showed a statistically significant difference for tryptophan, alanine, isoleucine, leucine, and valine among the nine AAs, which were associated with reduced insulin secretion during the follow-up.

Association of AAs With Fasting and 2-h Glucose Levels and Incident Type 2 Diabetes in a Prospective Study

All AAs that were significantly associated with reduced insulin secretion (phenylalanine, tryptophan, tyrosine, alanine, leucine, isoleucine, valine, aspartate, and glutamate) significantly increased fasting or 2-h glucose levels. All these AAs were also associated with higher risk of incident type 2 diabetes (N = 522), whereas glycine and glutamine were associated with a lower risk of type 2 diabetes (Table 3). In the follow-up study, tryptophan, alanine, isoleucine, and valine were associated with reduced insulin secretion and increased fasting and 2-h glucose levels but not with impairment in insulin sensitivity.

View this table:
  • View inline
  • View popup
Table 3

Associations of AAs with changes in glycemia and incident type 2 diabetes during the 7.4-year follow-up of the METSIM cohort

Discussion

We investigated the association of all twenty AAs with insulin secretion, insulin sensitivity, and fasting and 2-h glucose levels in a large randomly selected population-based METSIM cohort. Our 7.4-year follow-up study reports novel findings: 1) several AAs were associated with both impaired insulin secretion and impaired insulin sensitivity and 2) only the AAs that were associated with impaired insulin secretion prospectively were associated with an increase in glucose levels.

The novel finding in our METSIM 7.4-year follow-up study was that nine AAs (phenylalanine, tryptophan, tyrosine, alanine, isoleucine, leucine, valine, aspartate, and glutamate) were significantly associated with reduced insulin secretion, an important contributor in the conversion to diabetes. Among these nine AAs, five (phenylalanine, tyrosine, alanine, aspartate, and glutamate) were significantly associated with decreases in both insulin secretion and insulin sensitivity and five with incident type 2 diabetes (tyrosine, alanine, isoleucine, aspartate, and glutamate).

In our study, 17 of 20 AAs were associated with insulin resistance in cross-sectional analyses, in agreement with the results of earlier studies, but only 6 of them were associated with insulin resistance in our follow-up study. Our results agree with previous findings showing significant associations of branched-chain AAs (BCAAs) isoleucine, valine, and leucine with insulin resistance (10–13). However, in our study, BCAAs were also associated with reduced insulin secretion, suggesting that elevated levels of BCAAs may over time result in a decrease in insulin secretion. Impairment in BCAA catabolism has been suggested to result in the accumulation of potentially toxic intermediates that contribute to β-cell mitochondrial dysfunction and eventually to the apoptosis of β-cells (14).

We showed that phenylalanine and tyrosine were significantly associated with decreased insulin secretion and elevated levels of fasting and 2-h glucose in our follow-up study. We also confirmed the results of previous studies, which have shown that phenylalanine and tyrosine are significantly associated with insulin resistance and diabetes (15,16).

Tryptophan was associated with impaired insulin secretion in our prospective study. Tryptophan is an essential AA metabolized predominantly (∼95%) by the kynurenine pathway. Kynurenines are involved in inflammation, immune response, and excitatory neurotransmission (17). Previous studies have suggested that several metabolites of the kynurenine pathway are diabetogenic in humans (18). Tryptophan metabolites inhibit both proinsulin synthesis and glucose- and leucine-induced insulin release from rat pancreatic islets (19).

Glutamate and aspartate were significantly associated with decreased insulin secretion and increased insulin resistance in our follow-up study. A previous study has reported increased levels of glutamate in insulin resistance (20), but previous studies have not investigated the association of glutamate with insulin secretion in a prospective setting. In transgenic mice with β-cell–specific glutamate dehydrogenase deletion, glucose-stimulated insulin secretion was reduced by 37%, demonstrating the essential role of glutamate in the regulation of insulin secretion (21). The association of aspartate with increased risk of type 2 diabetes is a novel finding.

Alanine, one of the most abundant AAs in the circulation (22), was associated in our follow-up study with impaired insulin secretion and type 2 diabetes but not with insulin resistance. Glucagon is an important regulator of AA metabolism, and hyperglucagonemia is associated with increased levels of AAs, including alanine, aspartate, and glutamate (23). Unfortunately, we did not measure glucagon levels in our study.

Glycine was significantly associated with increases in insulin sensitivity and insulin secretion as previously published (24). Glycine stimulates insulin secretion by acting on glycine receptors and N-methyl-d-aspartate receptors in β-cells (24). Glycine also decreased fasting glucose nominally and 2-h glucose significantly, as previously reported (25), in agreement with its beneficial effects on insulin secretion and insulin sensitivity.

We summarize our results of effects of nine AAs (isoleucine, leucine, valine, phenylalanine, tyrosine, tryptophan, alanine, aspartate, and glutamate) on insulin sensitivity and insulin secretion in Fig. 1. The early effect of AAs on glucose metabolism seems to be an increase in insulin resistance given that the effect sizes of AAs (negative β) on insulin resistance were considerably larger than those on insulin secretion in a cross-sectional analysis. However, in the follow-up study the effects sizes of AAs (negative β) were consistently larger on reduction of insulin secretion than on insulin sensitivity. This suggests that AAs may have adverse effects on insulin secretion and consecutively on the risk of hyperglycemia and type 2 diabetes. Our study is, however, a prospective population-based study and cannot prove causality.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

AAs significantly associated with increased insulin resistance and reduced insulin secretion during a 7.4-year follow-up of the METSIM cohort. AAs significantly associated with type 2 diabetes after the adjustment for confounding factors are shown by red font.

The strengths of this study are a large and homogeneous study population and the validation of the methods used as surrogate markers for insulin sensitivity and secretion. We used a very conservative threshold for statistical significance to increase credibility of our conclusions. The limitation of the study is that only middle-aged and elderly Finnish men were included in the study, and therefore we do not know whether the results are valid for women, all age-groups, and other ethnic and racial groups. We are not aware of any unselected population sample where insulin and glucose measurements at 0, 30, and 120 min in an OGTT and metabolomics including all 20 AAs had been performed. Therefore, we could not replicate our findings in other populations.

In conclusion, we demonstrate that nine AAs were significantly associated with reduced insulin secretion and elevated glucose levels in a prospective population-based study of 5,181 Finnish men. Further studies are, however, needed to investigate the role of insulin secretion in diabetogenic effects of AAs.

Article Information

Funding. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under European Medical Information Framework grant agreement no. 115372 (to M.L. and U.S.). The METSIM study was supported by grants from Academy of Finland (321428), Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research, Kuopio University Hospital, and Centre of Excellence of Cardiovascular and Metabolic Diseases, supported by the Academy of Finland (to M.L.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. J.V. conceived the study, performed metabolomics and genetic data analyses, and wrote and revised the manuscript. A.S. performed metabolomics data analyses and revised the manuscript. U.S. and J.K. contributed to the discussion and revised the manuscript. M.L. conceived the study, wrote and reviewed the manuscript, and supervised the entire study. M.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-1076/-/DC1.

  • Received October 5, 2018.
  • Accepted March 9, 2019.
  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Laakso M,
    2. Kuusisto J
    . Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 2014;10:293–302pmid:24663222
    OpenUrlCrossRefPubMed
  2. ↵
    1. Newgard CB
    . Metabolomics and metabolic diseases: where do we stand? Cell Metab 2017;25:43–56pmid:28094011
    OpenUrlPubMed
    1. Stancáková A,
    2. Civelek M,
    3. Saleem NK, et al
    . Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes 2012;61:1895–1902pmid:22553379
    OpenUrlAbstract/FREE Full Text
    1. Lotta LA,
    2. Scott RA,
    3. Sharp SJ, et al
    . Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis. PLoS Med 2016;13:e1002179pmid:27898682
    OpenUrlPubMed
  3. ↵
    1. Guasch-Ferré M,
    2. Hruby A,
    3. Toledo E, et al
    . Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 2016;39:833–846pmid:27208380
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Laakso M,
    2. Kuusisto J,
    3. Stančáková A, et al
    . The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res 2017;58:481–493pmid:28119442
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Stancáková A,
    2. Javorský M,
    3. Kuulasmaa T,
    4. Haffner SM,
    5. Kuusisto J,
    6. Laakso M
    . Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 2009;58:1212–1221pmid:19223598
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Genuth S,
    2. Alberti KG,
    3. Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
    . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167pmid:14578255
    OpenUrlFREE Full Text
  7. ↵
    1. Matsuda M,
    2. DeFronzo RA
    . Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470pmid:10480510
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gannon MC,
    2. Nuttall FQ
    . Amino acid ingestion and glucose metabolism--a review. IUBMB Life 2010;62:660–668pmid:20882645
    OpenUrlCrossRefPubMed
    1. Newgard CB,
    2. An J,
    3. Bain JR, et al
    . A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311–326pmid:19356713
    OpenUrlCrossRefPubMedWeb of Science
    1. Würtz P,
    2. Tiainen M,
    3. Mäkinen VP, et al
    . Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012;35:1749–1756pmid:22563043
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Lee CC,
    2. Watkins SM,
    3. Lorenzo C, et al
    . Branched-chain amino acids and insulin metabolism: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2016;39:582–588pmid:26895884
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lynch CJ,
    2. Adams SH
    . Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014;10:723–736pmid:25287287
    OpenUrlCrossRefPubMed
  11. ↵
    1. Würtz P,
    2. Soininen P,
    3. Kangas AJ, et al
    . Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013;36:648–655pmid:23129134
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Palmer ND,
    2. Stevens RD,
    3. Antinozzi PA, et al
    . Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 2015;100:E463–E468pmid:25423564
    OpenUrlCrossRefPubMed
  13. ↵
    1. Cervenka I,
    2. Agudelo LZ,
    3. Ruas JL
    . Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science 2017;357:6349pmid:28751584
    OpenUrlPubMed
  14. ↵
    1. Oxenkrug G
    . Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 2013;48:294–301pmid:23813101
    OpenUrlCrossRefPubMed
  15. ↵
    1. Rogers KS,
    2. Evangelista SJ
    . 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets. Proc Soc Exp Biol Med 1985;178:275–278pmid:3881773
    OpenUrlCrossRefPubMed
  16. ↵
    1. Davalli AM,
    2. Perego C,
    3. Folli FB
    . The potential role of glutamate in the current diabetes epidemic. Acta Diabetol 2012;49:167–183pmid:22218826
    OpenUrlCrossRefPubMed
  17. ↵
    1. Carobbio S,
    2. Frigerio F,
    3. Rubi B, et al
    . Deletion of glutamate dehydrogenase in beta-cells abolishes part of the insulin secretory response not required for glucose homeostasis. J Biol Chem 2009;284:921–929pmid:19015267
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Salvucci M,
    2. Neufeld Z,
    3. Newsholme P
    . Mathematical model of metabolism and electrophysiology of amino acid and glucose stimulated insulin secretion: in vitro validation using a β-cell line. PLoS One 2013;8:e52611pmid:23520444
    OpenUrlCrossRefPubMed
  19. ↵
    1. Wewer Albrechtsen NJ,
    2. Junker AE,
    3. Christensen M, et al
    . Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. Am J Physiol Gastrointest Liver Physiol 2018;314:G91–G96pmid:28971838
    OpenUrlPubMed
  20. ↵
    1. Floegel A,
    2. Stefan N,
    3. Yu Z, et al
    . Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013;62:639–648pmid:23043162
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Wang-Sattler R,
    2. Yu Z,
    3. Herder C, et al
    . Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012;8:615pmid:23010998
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 68 (6)

In this Issue

June 2019, 68(6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men
Jagadish Vangipurapu, Alena Stancáková, Ulf Smith, Johanna Kuusisto, Markku Laakso
Diabetes Jun 2019, 68 (6) 1353-1358; DOI: 10.2337/db18-1076

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men
Jagadish Vangipurapu, Alena Stancáková, Ulf Smith, Johanna Kuusisto, Markku Laakso
Diabetes Jun 2019, 68 (6) 1353-1358; DOI: 10.2337/db18-1076
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Low-Frequency Genetic Variant in the Hepatic Glucokinase Gene Is Associated With Type 2 Diabetes and Insulin Resistance in Chinese Population
  • Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion
  • Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke
Show more Genetics/Genomes/Proteomics/Metabolomics

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.